Amplia Therapeutics (ASX:ATX) said initiation activities for its pancreatic cancer trial in the US have started, focusing on the combination of the company's focal adhesion kinase inhibitor narmafotinib with chemotherapy Folfirinox for advanced pancreatic cancer patients, according to a Wednesday filing with the Australian bourse.

The company partnered with a contract research organization to manage clinical trial activities in the US, the filing said.

The trial will be run under the investigational new drug application for narmafotinib which was cleared by the US Food and Drug Administration, per the filing.

Shares rose nearly 2% in recent trade Wednesday.